Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Labetalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 14/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 14/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 14/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 13/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 13/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labetalol SCHEMBL9614383 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10450118 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL29710409 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Dilevalol SCHEMBL588720 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10356800 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL4582 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Dilevalol SCHEMBL79468 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL7273474 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL41231 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10882744 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2796 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-118526590-A | Application of neuropeptide Y as cough medicine target point | 广州医科大学附属第一医院（广州呼吸中心） | 2024-08-23 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118490632-A | Stable labetalol hydrochloride injection and preparation method thereof | 遂成药业股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| CN-117045610-B | High-stability dissolution labetalol hydrochloride composition and preparation method thereof | 杭州沐源生物医药科技有限公司 | 2024-04-30 | — | — | CN | claimed |
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | claimed |
| CN-117756659-A | Preparation method of labetalol hydrochloride | 重庆圣华曦药业股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| US-20240041773-A1 | POWDER MIXING DEVICE, AND USES THEREOF | UNIV CONNECTICUT (US) | 2024-02-08 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0266707-B1 | SUSTAINED RELEASE LABETALOL TABLET | SCHERING CORPORATION (US) | 1992-01-22 | — | — | EP | claimed |
| US-5001113-A | Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO., INC. (US) | 1991-03-19 | — | — | US | claimed |
| US-4940580-A | Sustained release labetalol tablets | SCHERING CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
| EP-0312283-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| EP-0266707-A2 | Sustained release labetalol tablet | SCHERING CORPORATION (US) | 1988-05-11 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| US-4328213-A | HYPOTENSIVE AGENTS, ANTIARRHTHYMIA AGENTS | SCHERING CORPORATION (US) | 1982-05-04 | — | — | US | claimed |